Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1 Notification of Major Interest in Shares

14 Feb 2011 14:57

RNS Number : 2030B
Akers Biosciences, Inc.
14 February 2011
 



Financial Services Authority

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Akers Biosciences Inc.

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (Group)

 

Legal & General Investment Management Limited (LGIM)

 

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

Legal & General Assurance Society Limited (LGAS & LGPL)

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

08 February 2011

6. Date on which issuer notified:

11 February 2011

7. Threshold(s) that is/are crossed orreached:

 

Group (Above 15%)

LGIM (Above 15%)

L&G (From 9% to 15%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

NPV

 11,000,000

L&G

28,035,000

25,375,000

2,660,000

15.04%

1.57%

 14,000,000

LGIM

(As on 16/12/2009)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 25,375,000

(L&G)

 

15.04%

 28,035,000

(LGIM)

16.61%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 28,035,000 -16.61%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 28,035,000 - 16.61%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 28,035,000 - 16.61%= Total Position)

Legal & General Group Plc (Direct) (L&G) ( 25,375,000 - 15.04%=LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) ( 25,375,000 - 15.04%= LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) ( 25,375,000 - 15.04%= LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

13. Additional information:

Notification using the total voting rights figure of 168,715,666

14. Contact name:

Paul Toon (LGIM)

15. Contact telephone number:

020 3124 3854

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDKQDPQBKDPBD
Date   Source Headline
10th Dec 201210:39 amRNSNotice of AGM
26th Nov 20127:00 amRNSDistribution Partnership Forged in China
22nd Oct 20127:00 amRNSIssue of Equity
8th Oct 201212:00 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSPrivate Placing
17th Sep 20127:00 amRNSHalf Yearly Report
28th Jun 20127:00 amRNSFinal Results
30th Mar 201210:06 amRNSHolding(s) in Company
27th Feb 20125:01 pmRNSDirectorate Change
6th Jan 20127:00 amRNSTrading Update
6th Dec 20117:00 amRNSLaunch of PIFA PLUSS PF4 Rapid Assay
7th Sep 20117:00 amRNSHalf Yearly Report
24th Aug 20117:00 amRNSClinical Trials Commenced: COPD Rapid Assay
30th Jun 20117:00 amRNSUS$3.2 Million Purchase Order for Revelar
10th May 20115:54 pmRNSResult of AGM
28th Apr 20113:41 pmRNSAnnual Report & Accounts & AGM Notice
27th Apr 20117:00 amRNSUS patent protection grant
18th Apr 20117:00 amRNSAsthma Breath Test - Clinical Trials
11th Apr 20117:02 amRNSFinal Results
11th Apr 20117:00 amRNSSupply Agreement & Technology Acquisition
8th Apr 20117:00 amRNSConclusion of HIT Study
16th Mar 20117:00 amRNSPatent Protection - Rapid Blood Cell Separator
2nd Mar 20114:20 pmRNSHolding(s) in Company
28th Feb 20117:00 amRNSTotal Voting Rights
14th Feb 20113:08 pmRNSTR-1 Notification of Major Interest in Shares
14th Feb 20112:57 pmRNSTR-1 Notification of Major Interest in Shares
10th Feb 20117:00 amRNSIssue of Equity & Director Shareholding
1st Feb 20117:00 amRNSPlacing
14th Jan 20117:00 amRNSBreathScan PRO Receives Regulatory Clearance
5th Jan 20117:00 amRNSTrading Statement
29th Dec 20107:00 amRNSOrder for Tri-Cholesterol Tests - Middle East
16th Nov 20101:14 pmRNSIssue of Equity
30th Sep 20103:57 pmRNSHalf Yearly Report
29th Sep 20107:00 amRNSPIFA Heparin/Platelet Factor-4 - New Data
6th Sep 20107:00 amRNSProduct Distribution Expansion: Middle East/India
12th Aug 20107:00 amRNSFurther Distribution Agreement - PIFA Heparin/PF4
21st Jul 20105:18 pmRNSResult of AGM
21st Jun 20107:00 amRNSFinal Results
18th Jun 20107:00 amRNSBreath Ketone Test - Positive Data
14th Jun 20107:00 amRNSUSA Distribution Agreement
9th Jun 20107:00 amRNSBreathScan Alcohol Detection - Product Extension
26th Mar 20104:52 pmRNSHolding(s) in Company
19th Mar 20101:00 pmRNSChange of Adviser
17th Mar 20107:00 amRNSBreathScan Licensing Agreement - UK & Ireland
16th Mar 20107:00 amRNSClinical Study Data - PIFA Heparin
18th Feb 20109:04 amRNSDirector/PDMR Shareholding
30th Dec 20097:00 amRNSDirectorate Change
17th Dec 20099:23 amRNSHolding(s) in Company
15th Dec 20097:00 amRNSABI Obtains GSA Contract
4th Dec 20097:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.